Literature DB >> 21315178

Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration.

Da-Qing Yang1, Marie-Jo Halaby, Yan Li, Jody C Hibma, Paul Burn.   

Abstract

Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by cerebellar ataxia and oculocutaneous telangiectasias. The gene mutated in this disease, Atm (A-T mutated), encodes a serine/threonine protein kinase that has been traditionally considered to be a nuclear protein controlling cell-cycle progression. However, many of the growth abnormalities observed in patients with A-T, including neuronal degeneration and insulin resistance, remain difficult to explain with nuclear localization of ATM. Here, recent advances in elucidating the cytoplasmic localization and function of ATM are reviewed. Particular attention is given to the role of ATM in insulin signaling and Akt activation. The potential for cytoplasmic ATM protein kinase to be an emerging therapeutic target for treating diabetes, cancer and neuronal degeneration is discussed.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21315178     DOI: 10.1016/j.drudis.2011.02.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  32 in total

1.  DNA damage triggers a chronic autoinflammatory response, leading to fat depletion in NER progeria.

Authors:  Ismene Karakasilioti; Irene Kamileri; Georgia Chatzinikolaou; Theodoros Kosteas; Eleni Vergadi; Andria Rasile Robinson; Iannis Tsamardinos; Tania A Rozgaja; Sandra Siakouli; Christos Tsatsanis; Laura J Niedernhofer; George A Garinis
Journal:  Cell Metab       Date:  2013-09-03       Impact factor: 27.287

Review 2.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more.

Authors:  Yosef Shiloh; Yael Ziv
Journal:  Nat Rev Mol Cell Biol       Date:  2013-03-13       Impact factor: 94.444

3.  ATM may be a protective factor in endometrial carcinogenesis with the progesterone pathway.

Authors:  Weiwei Shan; Chao Wang; Zhenbo Zhang; Xuezhen Luo; Chengcheng Ning; Yinhua Yu; Youji Feng; Chao Gu; Xiaojun Chen
Journal:  Tumour Biol       Date:  2015-01-22

4.  Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis.

Authors:  Michael E Grossmann; Da-Qing Yang; Zhijun Guo; David A Potter; Margot P Cleary
Journal:  Curr Pharmacol Rep       Date:  2015-04-01

Review 5.  Development of anticancer drugs based on the hallmarks of tumor cells.

Authors:  Natalia Bailón-Moscoso; Juan Carlos Romero-Benavides; Patricia Ostrosky-Wegman
Journal:  Tumour Biol       Date:  2014-01-29

6.  Impaired insulin-stimulated glucose transport in ATM-deficient mouse skeletal muscle.

Authors:  James Kain Ching; Larry D Spears; Jennifer L Armon; Allyson L Renth; Stanley Andrisse; Roy L Collins; Jonathan S Fisher
Journal:  Appl Physiol Nutr Metab       Date:  2012-12-20       Impact factor: 2.665

7.  Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signalling in skeletal muscle.

Authors:  James Kain Ching; Stephen H Luebbert; Roy L Collins; Zhihong Zhang; Nandhini Marupudi; Sankha Banerjee; Robin D Hurd; Lyle Ralston; Jonathan S Fisher
Journal:  Exp Physiol       Date:  2012-08-31       Impact factor: 2.969

Review 8.  Axis of ageing: telomeres, p53 and mitochondria.

Authors:  Ergün Sahin; Ronald A DePinho
Journal:  Nat Rev Mol Cell Biol       Date:  2012-05-16       Impact factor: 94.444

Review 9.  ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.

Authors:  Cyril Ronco; Anthony R Martin; Luc Demange; Rachid Benhida
Journal:  Medchemcomm       Date:  2016-11-30       Impact factor: 3.597

10.  ATM protein is located on presynaptic vesicles and its deficit leads to failures in synaptic plasticity.

Authors:  Graham Vail; Aifang Cheng; Yu Ray Han; Teng Zhao; Shengwang Du; Michael M T Loy; Karl Herrup; Mark R Plummer
Journal:  J Neurophysiol       Date:  2016-04-13       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.